Based on the strong evidence for the effectiveness and safety of topical mTOR inhibitors in the management of facial angiofibroma, topical sirolimus is recently approved by the FDA for the management of facial angiofibroma in the United States. Here, MTOR is linked to Adenoma sebaceum.